We are shaping the future of oncology for patients
2023 Corporate Values and Sustainability Report
Our socially-oriented mission drives our environmental, social and governance program.
Read Our New Report
Expanding our oncology pipeline
Discover our newest pipeline asset, XL309, and learn about our partnership with Insilico Medicine.
Read Our News
An exceptional employee experience
Experience more purposeful work and fulfilling opportunities.
See Open Jobs
Accelerating our impact in oncology
Develop next-generation cancer medicines with us.
Building a culture of inclusion
Learn about our journey in creating a diverse, collaborative workforce.
Inspired by science
Leveraging deep expertise in chemistry and biology, as well as strategic partnerships, we are advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, antibody-drug conjugates and other innovative treatments.
Our discovery teams are advancing multiple small molecule programs internally and through collaborations with Aurigene and STORM Therapeutics.
Our R&D programs include next-generation approaches to established targets, as well as opportunities to be first-in-class by applying a range of modalities and mechanisms of action across biologics and small molecules.